Home
Company
About Us
Company Profile
Management
Board of Directors
Scientific Advisory Board
Ethics Statement
Legal Statement
Company Overview
SEC Filings
News
Current Press Releases
Press Release Archive
Event Calendar
Radio Interview
Investor Info
Investor Relations
Stock Quotes
Email Alerts
RSS News Feeds
Investor Kit
Oral Interferon
Why Low-Dose Oral Interferon
Interferon Facts
Disease Information
Clinical Trials
Research Projects
Key Publications
Patents
Development Partners
MAXISAL®
Do You Have Dry Mouth
MAXISAL® Retailers
Publications & Patents
Maxisal Overview
Contact Us
Investor Relations
Research Department
Public Relations
MAXISAL® Orders
Current Press Releases
Press Release Archive
Event Calendar
Archive
More Articles...
Amarillo Biosciences Appoints Kimball Miller, MD as Medical Director
Texas Tech University to Create the West Texas Influenza Research Center
Amarillo Bioscience Partner CytoPharm to Conduct 144 Patient Phase 2 Hepatitis C Trial in Taiwan
Amarillo Biosciences Oral Warts Study Enrollment at Halfway Point
Amarillo Biosciences Enters Into a License and Supply Agreement with CytoPharm
Amarillo Biosciences Appoints Dr. Peter Mueller Chief Operating Officer and Director of Research
Amarillo Biosciences Files Patent to Treat Obesity with Oral Interferon
Amarillo Biosciences to Support Western Australian Human Influenza Clinical Trial
Amarillo Biosciences Announces Private Placement
Copyright © 2010 Amarillo Biosciences. All Rights Reserved.
